title: [Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis].
abstract: Eighteen patients with relapsed or refractory Hodgkin's disease (HD) have been treated with high-dose chemotherapy (BEAM regimen) followed by autologous peripheral stem cells and/or bone marrow rescue. There were no treatment-related deaths. Overall response rate was 82%. With a median follow-up of 10 months (3-24 months) overall survival and freedom from progression were 100 and 94% (95% confidence interval 58-97%), respectively. The use of peripheral stem cells in addition to bone marrow resulted in a significant shortening of the time to engraftment (p < 0.01). The BEAM regimen is an effective conditioning schedule which is well tolerated.
authors.forename: V V
authors.initials: VV
authors.lastname: Ptuskin
authors.forename: A L
authors.initials: AL
authors.lastname: Uss
authors.forename: E A
authors.initials: EA
authors.lastname: Demina
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Chervonobab
authors.forename: N F
authors.initials: NF
authors.lastname: Milanovich
authors.forename: N N
authors.initials: NN
authors.lastname: Tupitsyn
authors.forename: V B
authors.initials: VB
authors.lastname: Larionova
authors.forename: Z E
authors.initials: ZE
authors.lastname: Batan
authors.forename: N E
authors.initials: NE
authors.lastname: Kondrat'eva
authors.forename: V A
authors.initials: VA
authors.lastname: Zmachinskiĭ
authors.forename: L A
authors.initials: LA
authors.lastname: Andreeva
authors.forename: V M
authors.initials: VM
authors.lastname: Snegir'
authors.forename: D M
authors.initials: DM
authors.lastname: Mkheidze
authors.forename: K L
authors.initials: KL
authors.lastname: Chimishkian
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012008:Recurrence; D012074:Remission Induction; D014182:Transplantation, Autologous
chemical_list: D003561:Cytarabine; D005047:Etoposide; D008558:Melphalan; D002330:Carmustine
vernacular_title: Sverkhvysokodoznaia khimioterapiia s transplantatsieĭ autologichnykh kletok predshestvennikov gemopoéza u bol'nykh s prognosticheski neblagopriiatnym retsidivom i rezistentnym techeniem limfogranulematoza.